Important Notice to Long-Term Shareholders of Unicycive Therapeutics, Inc. (UNCY): Grabar Law Office Is Investigating Claims on Your Behalf

Core Viewpoint - Grabar Law Office is investigating claims on behalf of shareholders of Unicycive Therapeutics, Inc. regarding potential breaches of fiduciary duties by certain officers and directors of the company [1]. Group 1: Investigation Details - The investigation focuses on whether certain officers and directors of Unicycive Therapeutics, Inc. breached their fiduciary duties to the company [1]. - Shareholders who purchased Unicycive shares prior to March 29, 2024, and still hold them can seek corporate reforms and the return of funds at no cost [2][4]. Group 2: Allegations - A federal securities fraud class action complaint alleges that Unicycive's officers made false statements regarding the company's readiness to meet FDA manufacturing compliance requirements, overstating their regulatory prospects [3]. - The complaint claims that the public statements made by the defendants were materially false and misleading at all relevant times [3].